News & Updates

Supplementation with essential amino acid improves liver health in teen girls with PCOS

23 Apr 2024 by

Short-term supplementation with a selective essential amino acid (EAA)-containing product significantly improved liver-related outcomes among adolescent girls with polycystic ovarian syndrome (PCOS) in a recent study.

Supplementation with essential amino acid improves liver health in teen girls with PCOS

23 Apr 2024

Tirbanibulin 1% ointment for actinic keratoses passes muster in real world

21 Apr 2024

Tirbanibulin 1% ointment proves safe and effective in patients with multiple actinic keratoses (AKs) treated in real-world settings, as shown in a study.

Tirbanibulin 1% ointment for actinic keratoses passes muster in real world

21 Apr 2024

Do GLP1 receptor agonists increase thyroid cancer risk?

20 Apr 2024 by

Use of glucagon-like peptide 1 (GLP1) receptor agonists does not contribute to an elevated risk of thyroid cancer, as shown in a Scandinavian cohort study with a mean follow-up of nearly 4 years.

Do GLP1 receptor agonists increase thyroid cancer risk?

20 Apr 2024

LDL-C lowering with bempedoic acid reduces cardiovascular events in high-risk population

19 Apr 2024

The use of bempedoic acid helps lower low-density lipoprotein cholesterol (LDL-C) levels and subsequently reduce cardiovascular events in individuals at high cardiovascular risk, according to the CLEAR* Outcomes trial.

LDL-C lowering with bempedoic acid reduces cardiovascular events in high-risk population

19 Apr 2024

Olezarsen reduces triglyceride levels in adults with hypertriglyceridemia

19 Apr 2024 by

Monthly administration of olezarsen 50 or 80 mg significantly reduced triglyceride levels in patients with predominantly moderate hypertriglyceridemia (HTG) and elevated cardiovascular (CV) risk, according to the Bridge-TIMI 73a trial presented at ACC.24.

Olezarsen reduces triglyceride levels in adults with hypertriglyceridemia

19 Apr 2024

Is it safe to use GLP1 agonists, SGLT2 inhibitors in patients on multiple insulin injections?

18 Apr 2024

Patients using multiple insulin injections demonstrate no significant difference in changes to A1c, insulin requirements, or weight after a year of treatment with a sodium glucose transporter 2 (SGLT2) inhibitor or glucagon-like peptide 1 (GLP1) receptor agonist, as shown in a study.

Is it safe to use GLP1 agonists, SGLT2 inhibitors in patients on multiple insulin injections?

18 Apr 2024

Anlotinib plus etoposide/carboplatin improves survival in extensive-stage SCLC

18 Apr 2024 by

Use of anlotinib combined with etoposide and carboplatin (EC; chemotherapy) as first-line therapy for patients with extensive-stage small cell lung cancer (ES-SCLC) yields a significantly improved progression-free survival (PFS) as well as overall survival (OS) benefits when compared with chemotherapy, according to data from the phase III ETER701 trial presented at ELCC 2024.

Anlotinib plus etoposide/carboplatin improves survival in extensive-stage SCLC

18 Apr 2024

Inactivated vaccine receipt during natalizumab treatment safe, immunogenic in MS patients

17 Apr 2024

For patients with multiple sclerosis (MS) who are receiving treatment with natalizumab, getting shots with inactivated vaccines is safe and immunogenic, with the positive results persisting regardless of the duration of natalizumab therapy, as shown in a study.

Inactivated vaccine receipt during natalizumab treatment safe, immunogenic in MS patients

17 Apr 2024

Panobinostat plus vincristine/irinotecan shows potential in hepatoblastoma

17 Apr 2024

Use of panobinostat in combination with vincristine and irinotecan chemotherapy provides effective tumour response in models developed from patients with high-risk, relapsed, and treatment-refractory hepatoblastoma (HB), according to a study.

Panobinostat plus vincristine/irinotecan shows potential in hepatoblastoma

17 Apr 2024

GLP-1RAs may improve long-term liver outcomes in T2D patients with MASLD

17 Apr 2024

For patients with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD) cirrhosis, treatment with glucagon-like peptide-1 receptor agonists helps reduce the risk of hepatic decompensation, portal hypertension, hepatocellular carcinoma, and liver transplantation, according to a study.

GLP-1RAs may improve long-term liver outcomes in T2D patients with MASLD

17 Apr 2024

News & Updates

Filter by Specialty:

Specialty:

Supplementation with essential amino acid improves liver health in teen girls with PCOS

Supplementation with essential amino acid improves liver health in teen girls with PCOS

Tirbanibulin 1% ointment for actinic keratoses passes muster in real world

Tirbanibulin 1% ointment for actinic keratoses passes muster in real world

Do GLP1 receptor agonists increase thyroid cancer risk?

Do GLP1 receptor agonists increase thyroid cancer risk?

LDL-C lowering with bempedoic acid reduces cardiovascular events in high-risk population

LDL-C lowering with bempedoic acid reduces cardiovascular events in high-risk population

Olezarsen reduces triglyceride levels in adults with hypertriglyceridemia

Olezarsen reduces triglyceride levels in adults with hypertriglyceridemia

Is it safe to use GLP1 agonists, SGLT2 inhibitors in patients on multiple insulin injections?

Is it safe to use GLP1 agonists, SGLT2 inhibitors in patients on multiple insulin injections?

Anlotinib plus etoposide/carboplatin improves survival in extensive-stage SCLC

Anlotinib plus etoposide/carboplatin improves survival in extensive-stage SCLC

Inactivated vaccine receipt during natalizumab treatment safe, immunogenic in MS patients

Inactivated vaccine receipt during natalizumab treatment safe, immunogenic in MS patients

Panobinostat plus vincristine/irinotecan shows potential in hepatoblastoma

Panobinostat plus vincristine/irinotecan shows potential in hepatoblastoma

GLP-1RAs may improve long-term liver outcomes in T2D patients with MASLD

GLP-1RAs may improve long-term liver outcomes in T2D patients with MASLD